论文部分内容阅读
目的探讨血必净对治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效。方法选取66例AECOPD患者为研究对象,随机将其分为观察组和对照组,每组各33例,对照组患者接受西医疗法,观察组患者还额外接受血必净注射液的治疗,三天后比较两组患者的PEF、PaO_2、PaCO_2、SaO_2及治疗效果。结果观察组的PEF、PaO_2、SaO_2含量高于对照组,PaCO_2含量低于对照组,观察组的治疗效果优于对照组,P<0.01,差异具有统计学意义。结论血必净可以改善AECOPD的治疗效果,值得临床医师参考和借鉴。
Objective To investigate the clinical efficacy of Xuebijing in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Sixty-six patients with AECOPD were randomly divided into observation group and control group, with 33 cases in each group. Patients in control group received western medical therapy, and XueBijing injection was additionally received in observation group. After three days The PEF, PaO_2, PaCO_2, SaO_2 and the treatment effect were compared between the two groups. Results The contents of PEF, PaO_2 and SaO_2 in the observation group were higher than those in the control group, and the content of PaCO_2 in the observation group was lower than that in the control group. The treatment effect in the observation group was better than that in the control group, P <0.01. The difference was statistically significant. Conclusion Xuebijing can improve the therapeutic effect of AECOPD, it is worth for clinicians reference and reference.